Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| NextCure | 2025 | Post Ipo Equity | $21.5M | Beltsville |
| Braveheart Bio | 2025 | Series A | $185.0M | San Francisco |
| X4 Pharmaceuticals | 2025 | Post Ipo Equity | $155.3M | Cambridge |
| Valneva | 2025 | Post Ipo Debt | $215.0M | Saint-herblain |
| ReCode Therapeutics | 2025 | Debt Financing | $29.4M | Dallas |
| DarioHealth | 2025 | Post Ipo Equity | $17.5M | New York |
| Epigenic Therapeutics | 2025 | Series B | $60.0M | Shanghai |
| Avenzo Therapeutics | 2025 | Series B | $60.0M | San Diego |
| Congruence Therapeutics | 2025 | Series Unknown | $32.0M | Montréal |
| Apollomics | 2025 | Post Ipo Equity | $4.1M | Foster City |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 101 | NextCure | Post Ipo Equity | $21.5M | Beltsville, United States |
| 102 | Braveheart Bio | Series A | $185.0M | San Francisco, United States |
| 103 | X4 Pharmaceuticals | Post Ipo Equity | $155.3M | Cambridge, United States |
| 104 | Valneva | Post Ipo Debt | $215.0M | Saint-herblain, France |
| 105 | ReCode Therapeutics | Debt Financing | $29.4M | Dallas, United States |
| 106 | DarioHealth | Post Ipo Equity | $17.5M | New York, United States |
| 107 | Epigenic Therapeutics | Series B | $60.0M | Shanghai, China |
| 108 | Avenzo Therapeutics | Series B | $60.0M | San Diego, United States |
| 109 | Congruence Therapeutics | Series Unknown | $32.0M | Montréal, Canada |
| 110 | Apollomics | Post Ipo Equity | $4.1M | Foster City, United States |
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs.
Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.
X4 Pharmaceuticals is a clinical-stage oncology company developing oral small molecule CXCR4 antagonists for the treatment.
Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.
ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics.
DarioHealth is a digital therapeutics company engaged in the development and commercialization of patented and proprietary technology.
Epigenic Therapeutics is a drug development company that develops gene modulation therapies through the regulation of epigenetic mechanisms.
Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.
Congruence Therapeutics operates as a biotechnology company.
Apollomics is a biopharmaceutical company discovering and developing mono- and combination- oncology therapies to harness the immune system.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.
Noctrix Health is an early-stage medical device company that focuses on developing a revolutionary therapy for a chronic illness.
Leal Therapeutics develops novel therapeutics for patients.
ProVerum Medical is a medtech company that develops novel minimally invasive devices to treat benign prostatic hyperplasia.
Minghui Pharmaceutical is a biopharmaceutical business that specializes in immunology and oncology medicines for unmet needs.
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments.
Forte Biosciences is a biotechnology company that focuses on dermatology.
Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers.
Sirius Therapeutics is an innovative biotechnology company that focuses on RNAi therapies for cardiovascular diseases.
Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.
Rimag is a Shenzhen-based medical imaging service provider.
RayThera is dedicated to developing small molecule therapies specifically targeting unmet needs in immunology.
Lomond Therapeutics creates pharmacological platforms that target escape mutations.
Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.
OrbiMed has invested in 239 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
OrbiMed's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 16 different industry categories.
Among tracked funding rounds, Mineralys Therapeutics received $287.5M in a Post Ipo Equity round. OrbiMed's total known invested capital is $12.2B.
OrbiMed's average investment size is $87.5M across its portfolio of 239 companies.
Recent OrbiMed portfolio additions include NextCure, Braveheart Bio, X4 Pharmaceuticals, Valneva, ReCode Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors